Physician profile
Kent Willis
NPI 1114306131
$4,788.73
in general payments reported to CMS, 2019-2025
51 companies · $696 in 2025
The $696 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $547 · 2021: $715 · 2022: $743 · 2023: $946 · 2024: $814 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.41 |
| Education | $219.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.04 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astellas Pharma US INC | $428.95 | 2020-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $306.01 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $290.85 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.59 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $245.99 | 2020-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $186.37 | 2019-2023 | Jardiance, Mounjaro |
| Abbott Laboratories | $159.17 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $158.82 | 2019-2025 | |
| Amgen INC. | $129.40 | 2022-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $124.09 | 2023-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $119.81 | 2019-2024 | Ozempic |
| Phathom Pharmaceuticals, INC. | $99.43 | 2024-2025 | Voquezna |
| Pfizer INC. | $94.10 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $85.96 | 2022-2025 | Qelbree, Qelbree |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.